PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.25
Bid: 8.20
Ask: 8.30
Change: -0.35 (-4.07%)
Spread: 0.10 (1.22%)
Open: 8.50
High: 8.50
Low: 8.25
Prev. Close: 8.60
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Dealings

9 May 2023 14:08

RNS Number : 8291Y
Agronomics Limited
09 May 2023
 

9 May 2023

 

Agronomics Limited

("Agronomics" or the "Company")

Directors' Dealings

Agronomics, the leading listed company focused on the field of cellular agriculture, is pleased to confirm that Jim Mellon, Executive Director, a PDMR, purchased an additional 392,000 ordinary shares in the Company ("Ordinary Shares") at an average price of 11.56 pence per share on 5th May 2023.

Following these transactions, Jim Mellon is interested in a total of 154,553,366 Ordinary Shares, representing 15.56% of the issued capital, of which 139,448,641 are held by Galloway Limited and 12,722,764 are held by Shellbay Investments Limited, companies which are both indirectly wholly owned by Jim Mellon, and 2,381,961 Ordinary Shares are held directly by Mr Mellon.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU No. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

 

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and be fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

 

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists' claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5℃.

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however, still, less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

For further information please contact:

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord Genuity Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

 

 

1

Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated

a)

Name

Jim Mellon

2

Reason for notification

a)

Position / status

Executive Director

b)

Initial notification

/Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Agronomics Limited

 

b)

LEI

21380029M8MPIEQ3TL31

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

392,000 Ordinary shares of £0.000001 each in Agronomics Limited

 

 

ISIN IM00B6QH1J21

Nature of the transaction

Market purchase of Ordinary Shares

 

c)

Price(s) and volumes(s)

 

Price(s)

Volumes(s)

 11.56 pence

392,000

 

 

d)

Aggregated information

n/a

e)

Date of the transaction

4 & 5 May 2023

f)

Place of the transaction

On market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUPUMUAUPWGWB
Date   Source Headline
23rd Dec 201612:00 pmRNSFinal Results and Notice of AGM
22nd Dec 20162:41 pmRNSLoan to the Diabetic Boot Company Ltd
12th Oct 20167:00 amRNSNet Asset Value(s)
22nd Jul 20167:00 amRNSNet Asset Value(s)
29th Apr 20167:00 amRNSNet Asset Value calculation to 31 March 2016
15th Apr 20167:00 amRNSChange of Adviser
18th Mar 20167:00 amRNSHolding(s) in Company
17th Mar 20167:00 amRNSInterim Results for the six months to 31 Dec 2015
10th Feb 201612:11 pmRNSResult of AGM
25th Jan 20167:00 amRNSNet Asset Value(s)
22nd Dec 20157:00 amRNSAnnual Audited Results and Notice of AGM
17th Dec 20154:00 pmRNSDBC receives US FDA approval to market PulseFlowDF
4th Nov 20157:00 amRNSNet Asset Value(s)
30th Jul 20157:01 amRNSNet Asset Value(s)
15th Apr 20157:00 amRNSNet Asset Value as at 31 March 2015
30th Mar 20157:00 amRNSInterim results for 6 months to 31 December 2014
6th Feb 201512:21 pmRNSClose of Tender Offer
4th Feb 20155:36 pmRNSRe Results of Tender Offer
2nd Feb 20158:00 amRNSResults of Tender Offer
23rd Jan 20157:00 amRNSHolding(s) in Company
15th Jan 201511:56 amRNSHolding(s) in Company
14th Jan 20157:00 amRNSTender Offer
12th Jan 20159:32 amRNSNet Asset Value
30th Dec 20147:00 amRNSAnnual audited results
23rd Dec 201411:58 amRNSHolding(s) in Company
28th Nov 20142:04 pmRNSTender Offer in respect of Magna Biopharma
21st Oct 20147:00 amRNSNet Asset Value to 30 September 2014
22nd Jul 20147:00 amRNSNet Asset Value(s)
8th Apr 20147:00 amRNSNet Asset Value calculations to 31 March 2014
31st Mar 20147:00 amRNSInterim Results for the six months to 31 Dec 2013
24th Jan 201411:21 amRNSHolding(s) in Company
20th Jan 201410:56 amRNSHolding(s) in Company
17th Jan 20147:00 amRNSNet Asset Value(s)
15th Jan 20147:00 amRNSAppointment of Nominated Adviser
6th Jan 20145:49 pmRNSHolding(s) in Company
20th Nov 20134:04 pmRNSHolding(s) in Company
13th Nov 20135:13 pmRNSHolding(s) in Company
12th Nov 20137:00 amRNSResult of General Meeting
24th Oct 20137:01 amRNSNotice of General Meeting
24th Oct 20137:00 amRNSAnnual Financial Report
18th Oct 201311:23 amRNSHolding(s) in Company
18th Oct 20137:00 amRNSNet Asset Value(s)
4th Oct 20132:13 pmRNSHolding(s) in Company
26th Sep 20135:10 pmRNSHolding(s) in Company
13th Sep 201311:32 amRNSHolding(s) in Company
6th Sep 20135:29 pmRNSHolding(s) in Company
6th Aug 20139:40 amRNSHolding(s) in Company
11th Jul 20137:00 amRNSNet Asset Value(s)
15th Apr 201312:34 pmRNSDirectorate Change
12th Apr 20132:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.